Kineta Past Earnings Performance
Past criteria checks 0/6
Kineta's earnings have been declining at an average annual rate of -14.6%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 45.2% per year.
Key information
-14.6%
Earnings growth rate
-8.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -45.2% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kineta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -17 | 9 | -3 |
| 30 Jun 24 | 0 | -21 | 10 | 0 |
| 31 Mar 24 | 5 | -18 | 12 | 0 |
| 31 Dec 23 | 5 | -14 | 12 | 0 |
| 30 Sep 23 | 6 | -58 | 13 | 7 |
| 30 Jun 23 | 6 | -59 | 13 | -7 |
| 31 Mar 23 | 2 | -65 | 11 | 0 |
| 31 Dec 22 | 2 | -63 | 9 | 0 |
| 30 Sep 22 | 3 | -20 | 7 | 4 |
| 30 Jun 22 | 5 | -17 | 6 | 15 |
| 31 Mar 22 | 7 | -14 | 5 | 12 |
| 31 Dec 21 | 9 | -12 | 5 | 16 |
| 31 Dec 20 | 10 | -8 | 4 | 9 |
Quality Earnings: KANT is currently unprofitable.
Growing Profit Margin: KANT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KANT is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.
Accelerating Growth: Unable to compare KANT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KANT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: KANT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.